In a market driven by speed, efficacy, and cost—and a perception that alpha-blockers are all the same—we successfully positioned RAPAFLO® as the alpha-blocker that delivers unsurpassed performance and maximum value for new patient starts.
We leveraged the unique selectivity profile of RAPAFLO®, starting with a message of speed and endurance and evolving to relief of the most bothersome BPH symptoms.
In the 5 years since launch, RAPAFLO® has continued to meet or exceed sales goals each year, and has surpassed market share goals.
Interferons had earned themselves a bad name in melanoma, known for long and protracted regimens, poor tolerability, and limited efficacy.
Enter Wedgewood. We understood that to transform a product’s reputation, you have to change what customers can expect when they see your brand.
For the launch of Sylatron®, we challenged the thinking about existing interferon protocols—and promoted a new and more tolerable regimen that delivered significant improvements in relapse-free survival.
In a changing market, Wedgewood worked to maintain the position of PegIntron® as the cornerstone of hepatitis C therapy, and the interferon of choice.
We developed intensive and integrated marketing, sales, and educational materials that reinforced dosing flexibility, uncompromised control, optimal tolerability, and an unmatched level of support for professionals and patients.
Physicians needed an antidiabetes medication that provided glucose control without increasing the risk of cardiovascular events.
The groundbreaking SAVOR study—the largest cardiovascular outcomes trial to date in type 2 diabetes patients at high risk for cardiovascular events—demonstrated that Onglyza® produced no increased risk of myocardial infarction, ischemic stroke, or cardiovascular death.
Wedgewood took this information and wove it seamlessly into a global Onglyza® campaign, successfully positioning it as the medication that could be prescribed with a higher level of confidence.
The USN is based on a simple idea: Provide physicians and practitioners with important, cutting edge, and up-to-the minute information across a range of urology topics to help them provide the best care for their patients while improving their practices.
Since its launch, the USN has become a knowledge passport for the urology community for easy, real-time access to the most recent clinical papers, news, and articles—delivered to their email or mobile device.